Healthcare Pharmaceuticals Ltd (HPL) today announced the launch of Eli Lilly's Humalog 200 (Insulin Lispro 200 Units/ml) KwikPen in Bangladesh.
Humalog 200 is the concentrated, rapid-acting analogue insulin designed to improve blood sugar control in adults with both Type 1 and Type 2 diabetes.
According to a press release, the Humalog 200 is a US Food and Drug Administration-approved medicine manufactured by Eli Lilly and Company.
Over time, some diabetic patients may require a dosage increase of their insulin for improved glycaemic control. Patients who are obese, have high insulin resistance and require a large daily dose of mealtime insulin, Humalog 200 could be a comfortable option for them.
Clinical studies done on Humalog 200 have established equivalent efficacy and safety versus conventional 100-unit insulin but with half the volume which is a preferred need for patients.
Humalog 200 comes in an easy-to-use - KwikPen that holds twice as many insulin units and requires fewer pen changes every month, thus it offers cost-effectiveness to the patients also.
This pen is easier to use and administer the injection. Humalog 200 KwikPen is suitable for patients searching for convenient and comfortable mealtime intensification options.
“Diabetes is a big burden on the healthcare system in Bangladesh. More than 13 million people live with diabetes in the country and their treatments are individualized. The launch of Humalog 200 will open newer avenues in diabetes management and provide healthcare professionals with a better way to manage diabetes. Humalog 200 will be marketed and distributed in Bangladesh by Healthcare Pharmaceuticals Ltd, a leading life science organization that believes in innovation, patient benefit and compliance,” said Halimuzzaman, DMD and CEO of Healthcare Pharmaceuticals Ltd.
Lilly and Healthcare Pharmaceuticals Limited entered into an agreement for the distribution and promotion of Lilly products in Bangladesh.
“Type 2 diabetes is a progressive disease and in Bangladesh, many patients do not meet their treatment goals. Humalog 200 is a new, concentrated rapid-acting analogue insulin, that has been designed keeping patients' needs and convenience in mind,” said Prof A K Azad Khan, president of BADAS.
Humalog 200 is a prescription drug that should be taken only on advice from registered physicians who deals the diabetic patients.
When prescribed, it should be used as an adjunct to diet, exercise and metformin (if not contraindicated).
